Details for Patent: 9,326,981
Which drugs does patent 9,326,981 protect, and when does it expire?
Patent 9,326,981 protects KYNMOBI and is included in one NDA.
This patent has forty-eight patent family members in twenty countries.
Summary for Patent: 9,326,981
| Title: | Sublingual apomorphine | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The invention features methods involving the use of sublingual film formulations of apomorphine for treating Parkinson's disease. The methods involve providing the sublingual film formulation and administering the sublingual film formulation sublingually in the mouth of a subject by contacting sublingual mucosal tissue with the film. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Anthony John Giovinazzo, David Bruce Hedden, Marc L. de Somer, Nathan John Bryson | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Sunovion CNS Development Canada ULC , Sumitomo Pharma America Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/684,146 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 9,326,981: Apomorphine Sublingual Film Claims, Exclusivity and Patent LandscapeUS Patent 9,326,981 protects a Parkinson's disease treatment method using a multilayer, non-effervescent, mucoadhesive sublingual film containing an acid-addition salt of apomorphine. The principal commercial product associated with this technology is KYNMOBI, an apomorphine hydrochloride sublingual film approved by the FDA in 2020. The patent is method-of-treatment protection, not a broad composition claim. The strongest infringement position requires proof of all core elements: Parkinson's treatment, an apomorphine-containing film, separate apomorphine and pH-neutralizing layers, mucoadhesion, non-effervescence, and sublingual contact. A competing apomorphine product delivered by injection, infusion, tablet, or a materially different film architecture would not fall within claim 1 solely because it uses the same active ingredient. What does US Patent 9,326,981 protect?The patent protects a specific drug-delivery system and its administration for Parkinson's disease. Claim 1 is the controlling independent claim.
The claim is cumulative. Omitting any required limitation creates a potential non-infringement position, subject to claim construction and the doctrine of equivalents. The claim does not require a particular brand, manufacturer, polymer, antioxidant, particle size, dose, or plasma concentration unless those limitations are added through dependent claims. How broad is claim 1 of US 9,326,981?Claim 1 is broad within the sublingual-film field but narrow compared with a general apomorphine patent. Active ingredient scopeThe phrase “acid addition salt of apomorphine” covers apomorphine salts formed with an acid. Claim 2 narrows the scope to apomorphine hydrochloride, the salt used in KYNMOBI. Claim 1 is not limited to hydrochloride and could reach other pharmaceutically acceptable acid-addition salts if they satisfy the remaining limitations. The claim does not require a specific polymorph, particle morphology, assay, release rate, or excipient composition. Film structureClaim 1 requires at least two functional layers:
The claim does not expressly require the layers to be arranged in a particular order relative to the mucosa, although the specification and prosecution history could affect construction. Claim 16 adds a third layer positioned between the first and second layers. This layered arrangement is important. A homogeneous single-layer film may avoid literal infringement if it does not contain the required first and second layers. A two-layer film in which the neutralizing agent is distributed throughout both layers may create a claim-construction issue rather than an automatic infringement finding. Mucoadhesive and non-effervescent limitationsThe film must be both mucoadhesive and non-effervescent. The non-effervescent limitation separates the claimed technology from dosage forms that generate gas through an acid-base reaction. The mucoadhesive requirement is central to the claim. A rapidly dissolving oral strip that does not adhere to sublingual mucosa may present a stronger design-around position. The legal result would depend on how the patent defines mucoadhesion and whether the accused formulation has measurable adhesive behavior. Administration limitationsClaim 1 is a method claim. It requires placing the film sublingually in the subject's mouth and contacting sublingual mucosal tissue. Manufacture, sale, or possession of the film alone does not satisfy every express limitation of the claim, although those activities may create liability under other patent theories, including induced or contributory infringement. What do claims 2 through 16 add?The dependent claims create narrower positions around formulation, dose, particle engineering, and pharmacokinetics.
The dose claims have overlapping numerical ranges. Claims 10 through 13 are narrower than claim 8 but overlap one another at certain boundaries. For example, claim 12 covers approximately 25 to 35 mg, while claim 13 covers approximately 30 to 40 mg. A product at 32 mg could potentially fall within both claims if all other limitations are met. Claim 15 is potentially difficult to enforce because it requires evidence of an average circulating plasma concentration in a defined time window. It may be more useful as a fallback claim than as the primary commercial claim. What formulations are protected by US 9,326,981?The patent protects formulations with the following combination:
The dependent claims extend protection to formulations containing antioxidants, permeation enhancers, glycerol monostearate, polysaccharides, selected particle sizes, and specified dose bands. The claims do not expressly require:
Those unclaimed features may still appear in the specification or related patent families, but they do not limit the claims as written unless incorporated through claim construction. When does US Patent 9,326,981 lose exclusivity?The patent's ordinary 20-year term is calculated from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable terminal disclaimer. Public patent records identify a December 1, 2011 priority date for the relevant apomorphine film family. On that basis, the nominal statutory expiration is approximately December 1, 2032, before any patent-term adjustment. [1] The exact enforceable expiration date must be determined from the USPTO patent-term record because patent-term adjustment can extend the term beyond the basic 20-year calculation. FDA patent-listing dates and patent expiration dates should not be treated as substitutes for the USPTO term calculation. FDA regulatory exclusivityKYNMOBI was approved under NDA 210875 on May 29, 2020, for the acute intermittent treatment of “off” episodes in adults with Parkinson's disease. [2] The product used the 505(b)(2) pathway rather than an ordinary ANDA pathway because the approved product introduced a distinct sublingual film presentation of apomorphine. Apomorphine was not a new molecular entity in the United States. The principal FDA exclusivity relevant to KYNMOBI was therefore not five-year NCE exclusivity. The product received three-year exclusivity associated with new clinical investigations supporting the approved formulation and use. That exclusivity period did not extend to the 2032 patent expiration date.
What is the Orange Book status of US 9,326,981?US 9,326,981 is associated with the KYNMOBI regulatory product and its sublingual apomorphine film technology. The relevant Orange Book analysis should distinguish three items:
A method patent can be listed in the Orange Book when it claims an approved method of using the drug. Its listing can require an ANDA or 505(b)(2) applicant to address the patent through certification. For a listed method patent, an applicant may use a Paragraph IV certification if it asserts that the patent is invalid, unenforceable, or will not be infringed. A product seeking approval for a non-infringing use may use a section viii statement, where permitted, to carve out the patented method. The commercial impact depends on the exact Orange Book use code. If the listed use code tracks treatment of Parkinson's “off” episodes with a sublingual film, a competing product seeking the same approved indication would face greater patent-certification exposure than a product targeting a different disease, route, or dosage form. What Paragraph IV challenges and litigation affect KYNMOBI?The claims supplied do not establish a Paragraph IV challenge, ANDA filing, or litigation outcome. FDA Orange Book data can identify listed patents, but it does not provide a complete litigation history. A Paragraph IV challenge to US 9,326,981 would likely focus on four issues: Anticipation and obviousnessA challenger could combine prior art relating to:
The critical question would be whether one reference discloses the full combination, or whether a skilled person would have had a reason to combine the references with a reasonable expectation of success. Written description and enablementPotential challenges could address the breadth of “acid addition salt,” the range of mucoadhesive polymers, the range of pH-neutralizing agents, and the claimed plasma concentration. The more broadly the claims are construed, the more important the disclosure across the full claim scope becomes. InfringementA generic or follow-on product would need to assess whether its film has two separately identifiable layers and whether its formulation is non-effervescent and mucoadhesive. A design using a single homogeneous film, a non-mucoadhesive dosage form, or a different administration route could reduce literal infringement exposure. Regulatory timingIf an ANDA or 505(b)(2) applicant filed a Paragraph IV certification before patent expiration, litigation could trigger a 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and litigation events. The 30-month stay does not extend the patent term. No biosimilar pathway applies because apomorphine is a small-molecule active ingredient. The relevant competitive pathways are ANDA, 505(b)(2), and potentially a full NDA. Which companies are challenging the KYNMOBI patent estate?The principal commercial parties are:
Sunovion agreed to acquire Cynapsus in 2016 for approximately $624 million in cash, subject to transaction terms. The transaction transferred control of the development program and its associated intellectual-property assets to Sunovion. [3] The acquisition was a corporate transaction, not evidence that US 9,326,981 was licensed to a third-party generic manufacturer. How strong is the patent estate for apomorphine sublingual film?US 9,326,981 has meaningful commercial value because it combines active ingredient, dosage form, delivery route, formulation structure, and Parkinson's treatment in a single method claim. Its principal strengths are:
Its principal vulnerabilities are:
The estate is stronger against a direct KYNMOBI substitute than against a different apomorphine delivery platform. How does KYNMOBI compare with competing apomorphine products?
The patent is not a monopoly over apomorphine treatment. It is a barrier around a particular sublingual film architecture and its use in Parkinson's disease. What generic launch risks exist?A generic or follow-on entrant faces the greatest risk if it:
Possible design-around strategies include:
These approaches may create separate regulatory, formulation, or freedom-to-operate issues. Avoiding literal infringement of claim 1 does not eliminate risk under other patents in the family or related formulation patents. What manufacturing and geographic IP barriers exist?The patent is a United States right. It can block US manufacture, importation, sale, offer for sale, or use of an infringing product during the enforceable term. It does not directly control manufacturing or sales outside the United States. For international programs, separate national family members must be assessed in Europe, Canada, Japan, and other target markets. Patent-term dates, claim scope, opposition history, supplementary protection certificates, and national prosecution outcomes can differ materially from the US position. Manufacturing-related risks may also arise from unasserted or separately issued patents covering:
US 9,326,981 itself is primarily a treatment-method patent. It does not, based on the claims supplied, provide a standalone manufacturing-process monopoly. Key Takeaways
FAQsDoes US 9,326,981 cover all apomorphine products?No. It is limited to a specific sublingual film method for treating Parkinson's disease. Injectable, infused, tablet, and other delivery systems generally do not satisfy the claim as written. Can a single-layer apomorphine film avoid claim 1?Potentially. Claim 1 requires a first layer containing apomorphine particles and a second layer containing a pH-neutralizing agent. A single-layer design may avoid literal infringement, although related patents and the doctrine of equivalents must be evaluated separately. Does the patent require apomorphine hydrochloride?No. Claim 1 covers an acid-addition salt of apomorphine generally. Claim 2 narrows the claim to apomorphine hydrochloride. Is KYNMOBI protected by biologic exclusivity?No. KYNMOBI contains apomorphine hydrochloride, a small-molecule active ingredient. Competition would proceed through ANDA or 505(b)(2) mechanisms, not a biosimilar application. Does FDA approval automatically establish patent infringement?No. FDA approval and patent infringement are separate questions. A product can receive regulatory approval while patent litigation, a Paragraph IV certification, a use carve-out, or a non-infringement dispute remains unresolved. References
More… ↓ |
Drugs Protected by US Patent 9,326,981
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | ||||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | ||||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,326,981
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010259971 | ⤷ Start Trial | |||
| Australia | 2017200329 | ⤷ Start Trial | |||
| Australia | 2019200308 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
